High Prevalence of Reduced Fecundity in Men with Congenital Adrenal Hyperplasia
Overview
Authors
Affiliations
Context: Testicular adrenal rest tumors (TARTs) are regarded to contribute to the high prevalence of subfertility in males with congenital adrenal hyperplasia (CAH).
Objectives: Our objectives were to evaluate reduced fecundity and its possible causes in well-controlled adult males with CAH, and to investigate diagnostic tools for improved treatment monitoring with respect to fertility outcomes.
Design: In a cross-sectional study at the Department of Endocrinology at the University Hospital München, Germany, 22 adult male CAH patients (15 salt wasting and seven simple virilizing, age 19-48 yr) were clinically assessed according to their hormonal control. We performed testicular ultrasound (22 of 22), magnetic resonance imaging (18 of 22), and a semen analysis (19 of 22) in the participants.
Results: All patients had a pathological semen analysis. TART prevalence was 10 of 22 (eight salt wasting, two simple virilizing). Poor therapy control was present in five patients, and all five had TARTs. Of the other 17 well-controlled patients with normal or suppressed adrenal androgens and 17-hydroxyprogesterone levels, five presented with TARTs. There was a significant correlation between sperm concentration and functional testicular volume (r = 0.70; P = 0.002), TART volume (r = -0.70; P = 0.036), as well as inhibin B levels (r = 0.75; P < 0.0001), respectively. In several men, hormonal control parameters suggested hypogonadism, with glucocorticoid overtreatment as a relevant factor for poor semen quality.
Conclusions: Poor semen parameters are common in male CAH patients. TARTs, most likely reflecting undertreatment, as well as inhibin B are important indicators of fecundity. On the other hand, long-term glucocorticoid overtreatment also seems to contribute to low semen quality.
Long-term Complications and Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia.
Kilinc Ugurlu A, Ozsu E, Aycan Z J Clin Res Pediatr Endocrinol. 2024; 17(Suppl 1):60-65.
PMID: 39713888 PMC: 11730098. DOI: 10.4274/jcrpe.galenos.2024.2024-6-22-S.
Sarafoglou K, Merke D, Reisch N, Claahsen-van der Grinten H, Falhammar H, Auchus R J Clin Endocrinol Metab. 2023; 108(9):2154-2175.
PMID: 36950738 PMC: 10438890. DOI: 10.1210/clinem/dgad134.
Gusmano C, Cannarella R, Crafa A, Barbagallo F, La Vignera S, Condorelli R J Endocrinol Invest. 2022; 46(1):1-14.
PMID: 35842891 PMC: 9829634. DOI: 10.1007/s40618-022-01849-9.
Long-Term Outcomes of Congenital Adrenal Hyperplasia.
Nordenstrom A, Lajic S, Falhammar H Endocrinol Metab (Seoul). 2022; 37(4):587-598.
PMID: 35799332 PMC: 9449109. DOI: 10.3803/EnM.2022.1528.
Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.
Claahsen-van der Grinten H, Speiser P, Ahmed S, Arlt W, Auchus R, Falhammar H Endocr Rev. 2021; 43(1):91-159.
PMID: 33961029 PMC: 8755999. DOI: 10.1210/endrev/bnab016.